Indicator for local recurrence of hepatocellular carcinoma after proton beam therapy: analysis of attenuation difference between the irradiated tumor and liver parenchyma on contrast enhancement CT.
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
pubmed:
2
11
2019
medline:
24
12
2019
entrez:
1
11
2019
Statut:
ppublish
Résumé
We aimed to identify dynamic CT features that can be used for prediction of local recurrence of hepatocellular carcinoma (HCC) after proton beam therapy (PBT). We retrospectively retrieved CT scans of patients with PBT-treated HCC, taken between January 2004 and December 2016. 17 recurrent lesions and 34 non-recurrent lesions were retrieved. The attenuation difference between irradiated tumor and irradiated parenchyma (AD The follow-up time after PBT initiation ranged from 374 to 2402 days (median, 1069 days) in recurrent lesions, and 418 to 2923 days (median, 1091.5 days) in non-recurrent lesions ( The attenuation difference between irradiated HCC and irradiated liver parenchyma in portal venous phase at 1-2 years after PBT can predict long-term local recurrence of HCC after treatment. We identified a cut-off value for contrast enhancement of HCC after PBT that could predict future local recurrence.
Identifiants
pubmed: 31670572
doi: 10.1259/bjr.20190375
pmc: PMC6948081
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20190375Références
AJR Am J Roentgenol. 2013 Dec;201(6):W812-20
pubmed: 24261388
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1039-45
pubmed: 20888707
J Comput Assist Tomogr. 1999 Sep-Oct;23(5):655-63
pubmed: 10524841
Strahlenther Onkol. 2009 Dec;185(12):782-8
pubmed: 20013087
Clin Radiol. 1999 Apr;54(4):253-6
pubmed: 10210346
World J Gastroenterol. 2018 Jul 28;24(28):3090-3100
pubmed: 30065555
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):407-21
pubmed: 12023146
Cancer Sci. 2017 Mar;108(3):497-503
pubmed: 28012214
Oncotarget. 2017 Dec 19;9(3):4034-4043
pubmed: 29423102
Br J Radiol. 2010 Dec;83(996):1063-71
pubmed: 21088090
Jpn J Clin Oncol. 2016 Oct;46(10):885-892
pubmed: 27534798
Clin Cancer Res. 2005 May 15;11(10):3799-805
pubmed: 15897579
Expert Rev Anticancer Ther. 2017 Oct;17(10):911-924
pubmed: 28825506
Jpn J Radiol. 2018 Apr;36(4):241-256
pubmed: 29508261
PLoS One. 2016 Dec 1;11(12):e0167155
pubmed: 27907063
Radiology. 1995 Nov;197(2):351-6
pubmed: 7480676
Future Oncol. 2016 Dec;12(23):2729-2739
pubmed: 27576360
Hepatol Res. 2016 Mar;46(5):483-8
pubmed: 26286377
Med Phys. 2001 Jul;28(7):1431-5
pubmed: 11488575
Radiother Oncol. 2017 May;123(2):240-245
pubmed: 28366501
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Magn Reson Imaging. 2001 Jan;19(1):41-6
pubmed: 11295345
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):460-6
pubmed: 19427743
Magn Reson Imaging. 2000 Jul;18(6):707-14
pubmed: 10930780
J Oncol. 2019 Jul 4;2019:3580379
pubmed: 31354819
Lancet Oncol. 2016 Feb;17(2):e49
pubmed: 26723084
J Radiat Res. 2012 Nov 1;53(6):945-53
pubmed: 22966173